Stem Cell Treatment for Cerebral Palsy: What It Involves, Who It Is For, and What the Results Show

Is Stem Cell Therapy the Future of Cerebral Palsy Treatment?

For those living with cerebral palsy, the search for effective treatments has often been met with limited options mainly focused on symptom management. Stem cell therapy takes a different approach: it aims to influence biological processes related to the underlying brain injury by supporting the brain’s repair processes and neuroplasticity, with the goal of improved function and a better quality of life (1, 2, 3).

Read on to see what it involves, who it is for, and what the evidence and our own results show.

Is Stem Cell Therapy a Cure for Cerebral Palsy?

No. Stem cell therapy does not cure cerebral palsy.

What the published studies and our own follow-up data describe is improvement in specific functions, most consistently gross motor function and muscle tone, in many children, though not in all. The gains measured in controlled trials are modest, and they were seen in children who continued their rehabilitation. Clinical benefit is not guaranteed, the degree of improvement differs considerably from one child to another, and the treatment remains experimental (2, 3, 4).

What the most recent research shows

Cerebral palsy has one of the largest bodies of controlled evidence among the conditions we treat. The most careful analysis is a 2025 individual participant data meta-analysis published in Pediatrics, which obtained 498 individual data records, covering 447 children and young people, from 11 studies of umbilical cord blood. Children given cord blood scored 1.36 points higher on the GMFM-66 gross motor scale than controls at 6 months and 1.42 points higher at 12 months, with no difference at 1 or 3 months. Two findings are relevant to families. The effect grew with the cell dose and was close to zero below about 50 million cells per kilogram. The children who benefited were mainly those under about 5 years old who could already move with some independence (GMFCS levels I to III). At GMFCS levels IV and V no significant treatment effect was demonstrated (report summary, 2).

For mesenchymal stem cells, a 2025 review identified 30 published reports and 10 registered trials (1,292 people) and found a large pooled effect on gross motor function at 3, 6 and 12 months in six controlled studies, with substantial variation between them. It found no significant difference between intrathecal and intravenous delivery, or between one dose and several, although there were too few studies to rule out a difference. No phase 3 trial has been published, and almost a third of the patients in the literature were treated through compassionate access rather than in a trial (report summary, 3). A 2025 meta-analysis of 13 randomized trials of several cell types reached a similar conclusion, with the estimated effect becoming smaller after sensitivity analysis removed three studies responsible for much of the heterogeneity (report summary, 4). A 2026 updated meta-analysis of 10 controlled trials involving 621 patients also found an overall improvement in gross motor function at 12 months. When the studies were separated by cell product, the improvement remained significant in the studies of cord blood-derived mesenchymal stromal cells (MSCs), while the cord blood mononuclear cell subgroup did not reach statistical significance (5).

Real-world data are also encouraging. A 2024 compassionate-use study of 152 children treated with umbilical cord MSCs reported improvements across motor assessments, including a median 1.9-point increase in GMFM after four administrations, and younger children generally showed greater improvement (6).

Not every result has been clear-cut. A double-blind, sham-controlled trial from Tehran gave 108 children a single intrathecal dose of umbilical cord mesenchymal stem cells, cord blood cells or a sham procedure, and found significantly greater gross motor gains than sham with both cell types (10, 11). A 2026 follow-up analysis of the same trial used MR spectroscopy and found that neither treatment produced a significant overall change in the brain metabolites measured at 12 months. In the 73 children with usable scans, both cell groups improved significantly in gross motor function from baseline while the sham group did not, but the median gains of 11 and 9 points against 6 with sham did not differ significantly between groups in this smaller subgroup (report summary, 7). A 2023 Korean extension study found that gross motor gains in the year after an additional cord blood infusion were much smaller than in the first trial year (1.55 against 5.75 GMFM-66 points; 1.97 against 5.69 in children who received cord blood both times), and again that a higher cell dose did better. Because this was an open-label extension study, the finding does not prove that every second treatment will produce less improvement than the first (report summary, 8).

In summary, the trials show a modest improvement in gross motor function. It is strongest in younger and less severely affected children and at higher cell doses. There is no published confirmatory phase 3 trial and long-term evidence remains limited (2, 3, 4, 5, 8). All of our summaries are listed on the cerebral palsy medical reports index.

Who Is a Candidate for Stem Cell Treatment for Cerebral Palsy?

• Age: Both our experience and the pooled trial data suggest that a younger age at treatment gives better results. In the 2025 meta-analysis the clearest benefit was in children under about 5 years old (2).
• Severity: In the same analysis, children at GMFCS levels I to III showed a measurable gain in gross motor function, whereas a significant treatment effect was not demonstrated at levels IV and V (2). We treat children across the range, and families of more severely affected children will be told what can realistically be expected. In our experience, for these children the gains are more likely to be in tone, comfort, swallowing or alertness than in walking, although the pooled trials have not measured these outcomes.
• Dose: Higher cell doses have done better in trials. Our protocol delivers 120 to 340 million cells in total, depending on the child’s weight and individual treatment plan. The optimal dose for MSCs is still being studied (2, 3). Trial doses are usually measured per kilogram of body weight, and in the cord blood meta-analysis the effect was close to zero below about 50 million cells per kilogram (2). Our dose is a total that combines cord blood cells and cord tissue MSCs, so it cannot be compared directly, but for all but the smallest children it works out lower than that per kilogram.
• Rehabilitation: Stem cell therapy is used together with physiotherapy, speech therapy and the child’s other treatments. It does not replace them (1, 16, 17).
• Seizures and general health: Clinical trials in this area have generally excluded children with intractable or untreated epilepsy or very recent seizures. The medical review covers seizure control, the child’s general condition and fitness to travel (9, 10, 12, 13).

Suitability is decided case by case. Every enquiry goes to our medical department, which reviews the patient’s medical condition through our online medical evaluation system and only then recommends a specific treatment location and protocol. We recommend speaking to our specialists before you decide, so that you know what can realistically be expected in your case.

Send us the medical records and our team will come back to you.

Who May Not Be Suitable for Treatment?

Every patient is reviewed individually by our medical team before treatment is accepted. Treatment may be declined, postponed, or require additional medical evaluation when there is a condition that could increase the risks of stem cell administration, intravenous infusion, sedation, or lumbar puncture. Similar safety considerations have also been used as exclusion criteria in published clinical studies of cell therapy for cerebral palsy (10, 12, 13).

Possible exclusion or temporary deferral criteria include:

• Active infection, fever, or another acute illness at the planned time of treatment
• Uncontrolled or recently active seizures, unstable hydrocephalus, or another neurological condition that may increase treatment or procedural risk
• A progressive neurological or genetic disorder when the diagnosis or clinical course is not consistent with stable cerebral palsy and requires further assessment
• Active cancer or a history of cancer that requires further medical assessment before treatment
• Severe or uncontrolled heart, lung, liver, kidney, or other major organ dysfunction
• Significant blood-clotting abnormalities or another condition that may make lumbar puncture unsafe
• Severe immune deficiency, autoimmune disease requiring immunosuppressive treatment, or another significant immune-system disorder requiring individual medical assessment
• A history of severe allergic reactions, particularly reactions to blood or biological products, when relevant to the planned treatment
• A medical condition that makes intravenous infusion, sedation, or intrathecal administration unsafe
• Any other significant medical condition that our medical team considers to make the potential risks of treatment greater than the expected benefit

These are general safety considerations rather than absolute exclusions in every case. Some conditions may only require treatment to be postponed until the patient has recovered or become medically stable, while others may require additional investigations or modification of the treatment protocol. Final eligibility is determined individually after review of the patient’s medical history, current condition, medications, seizure history and control, laboratory results and relevant medical reports.

What Proportion of Applications Are Declined?

We do not currently publish an overall acceptance or rejection percentage. Each application is reviewed individually, and some patients may be accepted immediately, while others may require additional medical information, treatment of an existing condition, a period of neurological or general medical stability, modification of the proposed protocol, or may ultimately not be considered suitable for treatment.

How Stem Cell Therapy Works in Cerebral Palsy

Cerebral palsy (CP), also first known as Little’s disease, is the most common cause of physical disability in children (17). Its prevalence varies between populations and is approximately 1.6 per 1,000 live births in many high-income countries, with higher rates reported in some low- and middle-income settings (1).

Despite the current lack of a curative treatment, stem cell therapy has been investigated as a novel treatment for CP, with the aim of supporting repair and neuroplasticity within the injured developing brain (1, 2, 3, 4).

Stem cells have the ability to develop into different cell types. However, research now suggests that in cerebral palsy their potential benefit may come mainly from the signals and growth factors they release rather than simply replacing damaged brain cells. This is known as a paracrine effect. These signals may help create a more favourable environment for the brain to protect surviving cells, control inflammation, improve blood supply and support its own repair and neuroplasticity (3, 9, 13, 14, 15, 20, 21).

Some clinical studies have also reported improvements in motor function together with measurable changes in brain connectivity and white-matter pathways after stem cell treatment (9, 10, 11, 14).

In the case of CP and other neurological disorders, stem cells may therefore offer neuroprotective and regenerative-supporting effects through several proposed mechanisms, most of them shown in laboratory and animal studies rather than in patients (3, 9, 13, 14, 15, 20, 21):

• Increasing the production and activity of neurotrophic factors that may promote neuronal survival, growth and repair (ex. glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF))
• Supporting oligodendrocyte survival, white-matter repair and white-matter organization, which may help the processes involved in myelination and neural signal transmission that can be affected in some forms of CP
• Modulating the immune system and the ongoing inflammatory process, thereby potentially reducing the ongoing neurodestructive process (secondary inflammatory damage within the brain)
• Promoting vascular and trophic support to the nervous system through stimulating the generation of new blood vessels (neovascularization) and improving the environment surrounding injured nervous tissue
• Stimulating and supporting neuroplasticity/brain connectivity by influencing neural and synaptic repair, allowing surviving areas of the brain to form and strengthen neural connections
• Modulating microglial activity, which plays an important role in inflammation and repair within the brain
• Reducing oxidative stress, including free radicals and reactive oxygen species that can contribute to neuronal injury and apoptosis

What are the Benefits of Stem Cell Therapy in Cerebral Palsy

An uncontrolled study reported functional improvements in 85% (17 of 20) of a small group of children with CP treated with autologous bone-marrow-derived cells by lumbar injection alongside intensive rehabilitation. Improvement was most often in muscle tone, limb strength or speech, and included changes reported by parents; only 3 of the 20 children improved on a standard measure of independence (19). Stem cell therapy aims to support neurological repair and reduce secondary processes such as inflammation, and it might support recovery from some consequences of the original brain injury. Controlled trials have mainly measured, and shown gains in, gross motor function (2, 3, 4, 20). Smaller, mostly uncontrolled studies have also reported changes in other areas (19), including:

• Gross motor functions: Such as walking, jumping, kneeling, sitting, and crawling
• Fine motor functions: Such as different hand functions
• Muscle tone: Reductions in spasticity and abnormal muscle tone have been reported in some studies
• Cognitive functions: Such as alertness and concentration
• Speech and language
• Swallowing and drooling
• Self-dependence
• Social-adaptability
• Visual function: Assessed or reported in some studies, but evidence for improvement in visual acuity specifically is limited
• Psychiatric and physical health: Including better mood and quality of life reported in some studies

Although stem cell therapy may provide significant benefits for some people with CP, it should still be used in combination with other treatment modalities rather than replace them, including physiotherapy, occupational therapy and speech therapy, all of which are available at Beike Technology, in order to support the best possible functional outcome (1, 16, 17).

Factors Affecting Response to Stem Cell Therapy

Given that this might be a difficult decision to make, and you might need to weigh the benefits versus risks prior to starting this journey, we will discuss with you different factors that might affect your child’s response to stem cell therapy, and how we at Beike Technology address each factor to ensure that we provide you with the highest efficacy using the safest procedure possible.

• Dose/Number of stem cells: Cell dose may influence treatment response. The higher the dose of stem cells, within limits of course, the better the response, although the optimal dose has not yet been established (2, 3). At Beike Technology, we administer a total dose of around 120-340 Million Cells (depending on the child’s weight and individual treatment plan).
• Route/Method of administration: How the cells are given may affect where they travel in the body and which tissues they can reach. The intravenous route provides systemic delivery (which causes stem cells to go to other organs than the brain before reaching the brain), while intrathecal injection (through lumbar puncture) places cells directly into the cerebrospinal fluid surrounding the brain and spinal cord. Both intravenous and intrathecal administration have been studied in cerebral palsy. At present, research has not clearly established that one route is consistently superior to the other (3). At Beike Technology, we use both intravenous and intrathecal routes concomitantly in order to obtain maximal efficacy; while ensuring the least possible side effects of toxicity.
• Age of transplant: There is some suggestion that the younger age of intervention has better results to stem cell therapy (2).
• Type of Stem Cells used: As previously mentioned, umbilical cord blood cells and umbilical cord tissue-derived MSCs are among the most extensively studied cell products in cerebral palsy. Both have shown encouraging safety and efficacy signals in published studies (2, 3, 5, 12). At Beike Technology, we use both forms of umbilical cord-based samples in patients with CP; umbilical cord blood and umbilical cord tissue.
• Follow-up Time: Changes in clinical studies are commonly assessed over several months, including at 3, 6 and 12 months after treatment. The timing and degree of improvement vary considerably between patients (2, 3). In our follow-up experience, improvements are often reported from around three months and may continue developing over the following 6 to 12 months. At Beike Technology, even after discharge, we provide you with a full follow-up program beginning as early as one month and up to one year after transplantation. You have complete access to our professional team even after you leave our center.

Possible Improvements after Stem Cell Therapy for Cerebral Palsy

The purpose of the treatment is to support the brain’s repair processes and neurological function. Thus, various kinds of improvement are possible after our treatment. The majority of Cerebral Palsy patients that have been treated by Beike, utilizing the combination of stem cell therapy and rehabilitation, showed visible signs of improvements, especially for these symptoms*:

Safety, Side Effects and Cell Quality Control

Stem cell treatment has generally been well tolerated in published cerebral palsy studies, but like any medical treatment, stem cell therapy can have side effects. Many of the short-term reactions reported are similar to those that can occur after an IV infusion or injection, such as fever, headache, nausea, vomiting, temporary discomfort, breathing difficulty or a temporary fall in oxygen levels during the infusion, or an allergic or immune reaction. Intrathecal administration also involves a lumbar puncture and may cause temporary procedure-related symptoms such as headache, back discomfort, nausea or vomiting (2, 3, 4, 10, 11, 12, 13).

In the 2025 meta-analysis of cord blood, serious adverse events occurred in 16.0% of treated children and 12.9% of those who did not receive cord blood, and only one was definitely related to treatment: a reaction to the cryoprotectant used to freeze the cells (report summary, 2). In the review of mesenchymal stem cell studies, no serious adverse events were reported; the side effects of intrathecal injection were fever, irritability, headache, low back pain, vomiting, nausea and neck stiffness, all resolving within days, and 7 of the 30 published reports gave no safety data at all (report summary, 3). In randomized trials, fever, vomiting and irritability were not significantly more common than in controls (report summary, 4).

Our protocol delivers cells both intravenously and by intrathecal injection, which is performed after a lumbar puncture, a procedure with its own risks (most commonly headache and back pain afterwards), which the treating physicians go through with you before you consent. Intrathecal CP trials have also reported transient headache, lower-back pain and irritability related to lumbar puncture (3, 10, 11).

On the cells themselves: a 2020 meta-analysis of 55 randomised trials, covering 2,696 adults given mesenchymal stromal cells into a vein or artery, found no increase in cancer compared with controls (22). A 2022 review of 361 people given donor umbilical cord blood for neurological conditions, including cerebral palsy, found no serious adverse events definitely or probably caused by the infusion and no tumour (teratoma) formation (23). In randomised trials of umbilical cord MSCs given into a vein or artery in adults, no increase in cancer has been seen so far either. However, only some trials reported on cancer, most followed patients for a year or less, and longer follow-up is still needed (18).

Every batch of cells is screened, tested twice and traceable by code before it is released for use. The full process is described on our standards and certifications page.

Where Treatment Happens, and Under Which Regulations

Treatment is delivered at affiliated hospitals in Bangkok, Thailand and in Dongguan, China. It is not approved by the US Food and Drug Administration and is not offered in the United States. It is given under Thai and Chinese regulations for cell therapy, and the cells are prepared in laboratories with CNAS, GMP and ISO accreditation. The accreditation details and the certificates are on our standards and certifications page.

Our Treatment Program in Details

Beike is unlike any other stem cell treatment provider in the world, the reason? Since 2005, we have been developing and optimizing our stem cell treatment protocols with the concept that a comprehensive treatment approach may provide more individualized support for our patients. We believe that stimulation through various therapies is necessary to enhance stem cell regenerative response, therefore our protocols include daily therapies to support the stem cells. Finally, we provide a wide variety and large quantities of stem cells in order to adapt to each patient’s specific condition and deliver maximized regenerative potential.

Our stem cell therapy program for cerebral palsy consists of 6 to 8 simple and minimally invasive injections of umbilical cord-derived stem cells. The stem cells are transplanted using two separate methods: by intravenous way using a standard IV drip system, and through intrathecal injection performed after lumbar puncture. These two delivery methods allow for increased efficacy while ensuring safety and minimum inconvenience for the patient.

Patient case Study - Cerebral Palsy Stem Cell Treatment

After a successful first stem cell treatment in Thailand in 2019, six young people with cerebral palsy travelled again from Poland for a second round of stem cells and supporting therapies. The families agreed to sit with us and tell us more about the improvements they have noticed so far and the treatment experience in general.

Watch more videos

Frequently Asked Questions

Q.Can stem cell therapy cure cerebral palsy?

A.

No. Stem cell therapy is not a cure for cerebral palsy. What controlled trials and our own follow-up data describe is a modest improvement in specific functions, most consistently gross motor function and muscle tone, for many, but not all, children, on top of rehabilitation. Improvement cannot be guaranteed and differs considerably from one patient to another (2, 3, 4).

Q.Is stem cell therapy for cerebral palsy approved by the FDA?

A.

No. Stem cell therapy for cerebral palsy is not approved by the US Food and Drug Administration, and we do not offer it in the United States. Treatment is delivered at affiliated hospitals in Thailand and China under those countries’ regulations for cell therapy. The laboratories that prepare the cells hold CNAS, ISO and GMP accreditation, which is not the same thing as FDA approval of the treatment. More detail is on our standards and certifications page.

Q.What is the Pathophysiology of Cerebral Palsy?

A.

Cerebral palsy results from abnormal development or non-progressive injury of the developing brain. There is no single cause or single biological pathway. Brain malformations, genetic factors, prematurity, stroke, infection, inflammation, hypoxic-ischaemic injury and other events occurring before, during or after birth, up to about two years of age, can contribute. The location and extent of brain injury influence the pattern and severity of symptoms (1).

The sequence differs according to the cause, but some important mechanisms include:

• An injury or disturbance occurs while the brain is still developing, from pregnancy through early childhood.
• The type and location of the injury can differ considerably between children.
• Some cases involve reduced blood or oxygen supply to the brain, inflammation, infection, stroke or abnormalities of brain development. Genetic factors can also contribute, and recent evidence suggests a genetic contribution in up to 30% of people with CP (1).
• In premature infants, white-matter injury can particularly affect developing oligodendrocytes, the cells involved in producing myelin around neuronal axons.
• Periventricular leukomalacia is one important form of white-matter injury associated particularly with prematurity; it is not present in every child with cerebral palsy.
• Damage to motor pathways and other brain networks can interfere with movement, posture, coordination and other neurological functions.
• The location and extent of the brain injury, together with the child’s development and associated conditions, influence the type and severity of symptoms.

Q.What are the Symptoms and Signs of Cerebral Palsy?

A.

Symptoms of CP differ greatly from one child to the other. It can also affect the whole body, or be limited to only one side of the body or even only one limb. It typically affects movement and coordination, speech and eating, development, as well as other problems (1).

Movement and Coordination

• Stiff muscles/Spasticity (the most common finding)
• Muscle tone abnormalities (Either being too stiff or too sloppy)
• Stiff muscles with normal reflexes (Rigidity)
• Tremors
• Lack of balance and coordination (Ataxia)
• Writhing movements
• Difficulty walking (ex. crouched gait/scissors-like gait/wide gait)
• Favoring one body side (ex. dragging on side while crawling/reaching out using one hand)
• Difficulty in fine motor skills (ex. using cutlery/buttoning their clothes)

Speech and Eating

• Speech delay
• Difficulty speaking
• Difficulty eating or chewing
• Excessive drooling

Development

• Learning difficulties
• Intellectual disability
• Growth delay (being shorter or thinner than expected for age)
• Delay in motor skills

Other Problems

• Seizures
• Hearing problems
• Vision problems or eye movement abnormalities
• Abnormal pain/touch sensation
• Bladder/Bowel problems (ex. constipation or urinary incontinence)
• Behavioral or psychiatric problems

Q.What are the Traditional Treatment Options for Cerebral Palsy?

A.

Treating CP usually involves a multidisciplinary team, including physiotherapists, occupational therapists, speech therapists, pediatric doctors, neurologists, orthopedic specialists and other professionals depending on the child’s needs. There is currently no cure, but these treatments can meaningfully improve daily function, participation, comfort and independence (1, 16, 17). Treatment differs according to the main symptoms and difficulties your child presents with. Current treatments that are widely used include:

Pharmacological/Medical Treatment

Medications are primarily used to treat problems such as muscle spasticity, which is commonly seen in CP and can cause pain and restrict movement and function. Treatment may include muscle relaxants and antispasticity treatments such as baclofen, botulinum toxin, diazepam and dantrolene, and in more severe cases intrathecal baclofen delivered through a pump. The choice of treatment depends on the type and severity of muscle tone abnormality and the child’s individual goals (1, 17).

Physiotherapy

Physiotherapy is one of the most importantly used treatment modalities. It can help improve muscle strength, mobility and gait and help prevent contractures and loss of movement. Modern rehabilitation places particular emphasis on active, goal-directed and task-specific exercises, where the child practices movements and activities that are important in everyday life (16, 17).

Occupational Therapy

Occupational therapy helps children improve their ability to perform everyday activities such as dressing, eating, playing, using their hands and participating at home and school. Specific approaches such as bimanual training or constraint-induced movement therapy may be useful for selected children, particularly those with greater difficulty using one hand (16, 17).

Speech and Communication Therapy

A speech therapist can be integrated into your child’s treatment plan in order to improve the clarity of their speech or to teach them to use sign language or other augmentative and alternative communication methods when appropriate (1, 16).

Surgical Intervention

This includes orthopedic surgeries for children with significant contractures, hip displacement or bone and joint deformities in order to reduce pain, improve positioning and, when possible, improve mobility. Surgeons might lengthen muscles or tendons in contracted areas. In the case of resistant cases, selective dorsal rhizotomy may be considered in carefully selected children to reduce lower-limb spasticity (1, 17).

Other treatments

Other treatments might be integrated depending on the child’s condition, including anticonvulsants for seizures, psychological or behavioral support, orthotic devices, mobility aids, nutritional support, treatment for pain and sleep problems, and management of vision or hearing difficulties. There is currently no treatment that cures or completely reverses cerebral palsy. This is where stem cell therapy is being investigated as an additional regenerative approach (1, 16, 17).

Q.What Types of Stem Cells are used to treat Cerebral Palsy?

A.

Several different cell products have been studied in cerebral palsy. The main products investigated in clinical studies include (2, 3, 4, 12, 13, 20):

• Umbilical cord-derived cell products (umbilical cord blood cells and umbilical cord tissue-derived MSCs): most widely available and generally well tolerated in clinical trials
• Bone marrow-derived stem cells
• Neural and other progenitor-cell approaches (more experimental)
• Embryonic stem cells (laboratory and animal research only)

In patients with CP, umbilical cord blood and umbilical cord-derived MSCs are two of the most actively studied cell products. At Beike Technology, our treatment protocol uses two forms of umbilical cord-derived cell products, umbilical cord blood-derived cells and umbilical cord tissue-derived MSCs, donated from healthy mothers after normal birth. The combined use of these products is part of our treatment approach as they have shown a favorable safety profile and encouraging clinical results (2, 3, 12).

Medically reviewed by

Dr. Mohammad Alzogool

Medical Director

Beike's Medical Director, Dr. Mohammad Alzogool, is a physician-researcher with a background in ophthalmology and regenerative medicine. His research contributions span ophthalmology, regenerative medicine, artificial intelligence, medical imaging, and evidence-based clinical guidelines. He brings a strong scientific and clinical perspective to the evaluation of emerging regenerative therapies.

Full profile LinkedIn ResearchGate

Published February 24, 2017 Last updated October 20, 2026

Published research

Research on cerebral palsy

Plain-language summaries of independent, peer-reviewed studies. Each one links to the original publication.

• Impact of Stem Cell Therapy on Brain Metabolic Profile in Cerebral Palsy Assessed by Magnetic Resonance Spectroscopy in a Randomized Clinical Trial 2026
• Evaluation of Stem/Stromal Cell Transplantation Safety and Efficacy in Children Diagnosed With Cerebral Palsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 2025
• Clinical Evidence of Mesenchymal Stromal Cells for Cerebral Palsy: Scoping Review With Meta-Analysis of Efficacy in Gross Motor Outcomes 2025
• Cord Blood Treatment for Children With Cerebral Palsy: Individual Participant Data Meta-Analysis 2025
• Maintenance of the Synergistic Effects of Cord Blood Cells and Erythropoietin Combination Therapy After Additional Cord Blood Infusion in Children With Cerebral Palsy: 1-Year Open-Label Extension Study of Randomized Placebo-Controlled Trial 2023
• Efficacy and Safety of Stem Cell Therapy in Cerebral Palsy 2022
• Autologous Cord Blood in Children with Cerebral Palsy 2019
• Cerebral Palsy: Diagnosis and Treatment 2021

All 16 studies on cerebral palsy

Medical References

1. 1. Novak I, Jackman M, Finch-Edmondson M, Fahey M. Cerebral palsy. Lancet. 2025;406(10499):174-188. https://doi.org/10.1016/S0140-6736(25)00686-5
2. 2. Finch-Edmondson M, Paton MCB, Webb A, et al. Cord Blood Treatment for Children With Cerebral Palsy: Individual Participant Data Meta-Analysis. Pediatrics. 2025;155(5):e2024068999. https://doi.org/10.1542/peds.2024-068999
3. 3. Paton MCB, Griffin AR, Blatch-Williams R, et al. Clinical Evidence of Mesenchymal Stromal Cells for Cerebral Palsy: Scoping Review with Meta-Analysis of Efficacy in Gross Motor Outcomes. Cells. 2025;14(10):700. https://doi.org/10.3390/cells14100700
4. 4. Fatahi R, Heydarpour F, Moradi Motlagh S, Mansouri K. Evaluation of stem/stromal cell transplantation safety and efficacy in children diagnosed with cerebral palsy: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2025;16:468. https://doi.org/10.1186/s13287-025-04550-9
5. 5. Duong A, Shorr R, Allan DS. An updated meta-analysis of umbilical cord blood to treat cerebral palsy: distinguishing cord blood infusions from mesenchymal stromal cell therapy. Curr Res Transl Med. 2026;74(1):103574. https://doi.org/10.1016/j.retram.2026.103574
6. 6. Chrościńska-Kawczyk M, Zdolińska-Malinowska I, Boruczkowski D, et al. The Impact of Umbilical Cord Mesenchymal Stem Cells on Motor Function in Children with Cerebral Palsy: Results of a Real-world, Compassionate use Study. Stem Cell Rev Rep. 2024;20(6):1636-1649. https://doi.org/10.1007/s12015-024-10742-2
7. 7. Jameie M, Pak N, Mozafar M, et al. Impact of stem cell therapy on brain metabolic profile in cerebral palsy assessed by magnetic resonance spectroscopy in a randomized clinical trial. Sci Rep. 2026;16:25999. https://doi.org/10.1038/s41598-026-50051-x
8. 8. Suh MR, Min K, Cho KH, et al. Maintenance of the synergistic effects of cord blood cells and erythropoietin combination therapy after additional cord blood infusion in children with cerebral palsy: 1-year open-label extension study of randomized placebo-controlled trial. Stem Cell Res Ther. 2023;14:362. https://doi.org/10.1186/s13287-023-03600-4
9. 9. Sun JM, Song AW, Case LE, et al. Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial. Stem Cells Transl Med. 2017;6(12):2071-2078. https://doi.org/10.1002/sctm.17-0102
10. 10. Amanat M, Majmaa A, Zarrabi M, et al. Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial. Stem Cell Res Ther. 2021;12:439. https://doi.org/10.1186/s13287-021-02513-4
11. 11. Zarrabi M, Ghahvechi Akbari M, Amanat M, et al. The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial. BMC Neurol. 2022;22(1):123. https://doi.org/10.1186/s12883-022-02636-y
12. 12. Sun JM, Case LE, McLaughlin C, et al. Motor function and safety after allogeneic cord blood and cord tissue-derived mesenchymal stromal cells in cerebral palsy: an open-label, randomized trial. Dev Med Child Neurol. 2022;64(12):1477-1486. https://doi.org/10.1111/dmcn.15325
13. 13. Gu J, Huang L, Zhang C, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 2020;11:43. The cells used in this trial were supplied by Shenzhen Beike Biotechnology. https://doi.org/10.1186/s13287-019-1545-x
14. 14. Min K, Song J, Kang JY, et al. Umbilical Cord Blood Therapy Potentiated with Erythropoietin for Children with Cerebral Palsy: A Double-blind, Randomized, Placebo-Controlled Trial. Stem Cells. 2013;31(3):581-591. https://doi.org/10.1002/stem.1304
15. 15. Kang M, Min K, Jang J, et al. Involvement of Immune Responses in the Efficacy of Cord Blood Cell Therapy for Cerebral Palsy. Stem Cells Dev. 2015;24(19):2259-2268. https://doi.org/10.1089/scd.2015.0074
16. 16. Morgan C, Fetters L, Adde L, et al. Early Intervention for Children Aged 0 to 2 Years With or at High Risk of Cerebral Palsy: International Clinical Practice Guideline Based on Systematic Reviews. JAMA Pediatr. 2021;175(8):846-858. https://doi.org/10.1001/jamapediatrics.2021.0878
17. 17. Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020;20(2):3. https://doi.org/10.1007/s11910-020-1022-z
18. 18. Hum C, Poliwoda J, Lalu MM, et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine. 2026;15(6):szag029. https://doi.org/10.1093/stcltm/szag029
19. 19. Sharma A, Gokulchandran N, Chopra G, et al. Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012;21 Suppl 1:S79-S90. https://doi.org/10.3727/096368912X633798
20. 20. Novak I, Walker K, Hunt RW, Wallace EM, Fahey M, Badawi N. Concise Review: Stem Cell Interventions for People With Cerebral Palsy: Systematic Review With Meta-Analysis. Stem Cells Transl Med. 2016;5(8):1014-1025. https://doi.org/10.5966/sctm.2015-0372
21. 21. Bufi AA, Papait A, Ponsaerts P, Silini AR, et al. Mesenchymal stromal cells and neuroinflammation: a multimodal approach to neuroprotection and future therapeutic horizons. Transl Neurodegener. 2026;15:23. https://doi.org/10.1186/s40035-026-00554-4
22. 22. Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;19:100249. https://doi.org/10.1016/j.eclinm.2019.100249
23. 23. Paton MCB, Wall DA, Elwood N, et al. Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies. Cytotherapy. 2022;24(1):2-9. https://doi.org/10.1016/j.jcyt.2021.07.001